Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7934895 | 0.94 | IGF1R (0.48) | CYP1A2CYP2A6TAAR1IGF1RALOX15 | |
| SCHEMBL13499925 | 0.86 | CYP1A2 (0.50) | CYP1A2CYP2A6TAAR1IGF1RALOX15 | |
| SCHEMBL15263304 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP2A6TAAR1IGF1RALOX15 | |
| SCHEMBL22753712 | 0.82 | CYP1A2 (0.42) | CYP1A2CYP2A6TAAR1IGF1RALOX15 | |
| SCHEMBL23279457 | 0.80 | CYP1A2 (0.41) | CYP1A2CYP2A6TAAR1IGF1RALOX15 | |
| SCHEMBL28134403 | 0.80 | ESR1 (0.56) | TAAR1IGF1RALOX15ESR1ADRA2A | |
| SCHEMBL31124935 | 0.80 | TAAR1 (0.48) | TAAR1IDO1MAPTALDH1A1PTGS1 | |
| SCHEMBL20445512 | 0.79 | ESR1 (0.62) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL31124934 | 0.78 | TAAR1 (0.57) | TAAR1IDO1PTPN2PTPN1PTPN6 | |
| SCHEMBL20575211 | 0.78 | TAAR1 (0.46) | CYP2A6TAAR1IDO1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118851917-A | Method for preparing beta-trifluoromethyl amine compound | 中山大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-1377289-A4 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | JB CHEMICALS & PHARMACEUTICALS (IN) | 2008-09-10 | — | — | EP | disclosed |
| EP-1691797-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | Pharmacia Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1569640-A4 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1569640-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005049014-A1 | COX-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES-RELATED OCULAR DISORDERS | PHARMACIA CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005041864-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005020926-A2 | TREATMENT OR PREVENTION OF VASCULAR DISORDERS WITH COX-2 INHIBITORS IN COMBINATION WITH CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1377289-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. Chemicals & Pharmaceuticals Ltd. (IN) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003059294-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2002074235-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. CHEMICALS & PHARMACEUTICALS LTD (IN) | 2002-09-26 | — | — | WO | disclosed |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | J.B. CHEMICALS & PHARMACEUTICALS LIMITED | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | AADAC, NAT1, FPR1 | CYP1A2 899/4885CYP2A6 997/4885TAAR1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.